Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesCellectar Biosciences Inc

Cellectar Biosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.31 USD 0.06 ( 4.80%)
Last update at 2026-11-09T14:58:00Z
VOLUME
4662
Market Cap
21.93M

Momentum Score

…

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.30
Low
1.31
High
52 Week Price Range
2.20
Low
6.52
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cellectar Biosciences is a clinical-stage biotechnology company developing phospholipid drug conjugates to deliver therapeutic and imaging agents to cancer cells. Long-term growth drivers include successful clinical progress and regulatory approval of its candidates, expansion into multiple cancer indications, and strategic partnerships to fund development. The platform may improve tumor targeting and selectivity, and positive clinical outcomes could enable commercialization opportunities.
Key risks are clinical and regulatory failure, limited operating history and need for external financing with potential dilution, and intense oncology competition that could constrain market uptake.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.25
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.04
ROE
-119.57%
Net Debt
-12.79M
ROCE
-224.66%
Diluted EPS TTM
-2.23

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -21.79M -44.52M -42.83M -28.66M -24.12M
Net income -21.79M -44.58M -42.77M -28.60M -23.97M
Selling general administrative 11.48M 25.64M 11.69M 9.59M 6.54M
Selling and marketing expenses - 0.95M 0.95M - -
Gross profit -0.21M -0.29M -0.19M - -
Reconciled depreciation 0.21M 0.29M 0.16M 0.15M 0.15M
Ebit -22.98M -51.78M -38.96M -28.96M -24.28M
Ebitda -22.77M -51.49M -38.77M -28.81M -24.13M
Depreciation and amortization 0.21M 0.29M 0.19M 0.15M 0.15M
Operating income -22.98M -51.78M -38.96M -28.81M -24.13M
Other operating expenses 22.98M 51.78M 38.96M 28.81M 24.13M
Interest expense - - - -0.30M 0.00M
Tax provision 0.00M 0.07M -0.06M -0.06M -
Interest income 0.44M 1.21M 0.40M 0.15M 0.00M
Net interest income 0.44M 1.21M 0.40M 0.15M 0.00M
Income tax expense - 0.07M -0.06M -0.06M -0.15M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 22.77M 51.78M 38.96M 28.81M 24.13M
Cost of revenue 0.21M 0.29M 0.19M - -
Total other income expense net 1.19M 7.26M -3.87M 0.15M 0.01M
Net income from continuing ops -21.79M -44.58M -37.75M -28.60M -24.12M
Net income applicable to common shares - - - -28.60M -24.12M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 14.98M 25.47M 12.08M 21.59M 37.20M
Other current assets 0.84M 0.96M 0.89M 0.66M 0.87M
Total liab 5.06M 11.18M 13.43M 6.08M 4.16M
Total stockholder equity 9.92M 14.29M -1.36M 15.51M 33.05M
Other current liab 3.21M 5.20M 7.26M 2.92M -0.00M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.52M 0.52M 6.06M 1.38M 1.38M
Retained earnings -269.13M -247.34M -217.48M -179.50M -150.90M
Other assets - - - 0.08M 0.08M
Cash 13.20M 23.29M 9.56M 19.87M 35.70M
Total current liabilities 4.75M 9.39M 12.94M 5.53M 3.99M
Current deferred revenue - - - - 2.44M
Net debt -12.79M -22.79M -9.01M -19.26M -35.40M
Short term debt 0.10M 0.08M 0.06M 0.05M 0.14M
Short long term debt total 0.41M 0.49M 0.55M 0.60M 0.30M
Other stockholder equity 277.15M 261.12M 211.45M 193.62M 182.56M
Property plant equipment - - - 0.98M 0.55M
Total current assets 14.04M 24.25M 10.45M 20.53M 36.57M
Net tangible assets - - - 14.13M 31.66M
Accounts payable 1.44M 4.11M 5.62M 2.56M 1.42M
Accumulated other comprehensive income - - -1.38M - -
Non currrent assets other 0.03M 0.03M 0.03M 0.08M 0.08M
Non current assets total 0.94M 1.22M 1.62M 1.06M 0.63M
Capital lease obligations 0.41M 0.49M 0.55M 0.60M 0.30M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.10M -0.72M -0.23M -0.14M
Change to liabilities - - - 1.62M 0.41M
Total cashflows from investing activities -0.01M -0.10M -0.86M -0.23M -0.14M
Total cash from financing activities 13.03M 61.41M 22.94M 9.61M 1.25M
Change to operating activities - - - 0.06M -0.21M
Net income -21.79M -44.58M -42.77M -28.60M -24.12M
Change in cash -10.09M 13.72M -10.30M -15.84M -21.46M
Begin period cash flow 23.29M 9.56M 19.87M 35.70M 57.17M
End period cash flow 13.20M 23.29M 9.56M 19.87M 35.70M
Total cash from operating activities -23.12M -47.58M -32.38M -25.22M -22.57M
Issuance of capital stock 5.79M 0.00M 31.76M 9.61M 0.03M
Depreciation 0.21M 0.29M 0.19M 0.15M 0.15M
Other cashflows from financing activities 13.03M 61.41M 22.94M -0.23M 1.21M
Change to netincome - - - 1.55M 1.20M
Capital expenditures 0.01M 0.10M 0.86M 0.23M 0.14M
Change in working capital -3.13M -1.73M 3.48M 1.68M 0.20M
Stock based compensation 2.26M 4.27M 2.41M 1.45M 1.12M
Other non cash items -0.68M -5.84M 4.32M 0.09M 0.08M
Free cash flow -23.12M -47.69M -33.24M -25.45M -22.71M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CLRB
Cellectar Biosciences Inc		 0.06
4.80%		 1.31 - - 348.47 0.73 314.45 -3.25
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

100 Campus Drive, Florham Park, NJ, United States, 07932

608 441 8120

https://www.cellectar.com

11

Name Title Year Born
Mr. James V. Caruso Pres, CEO & Director 1959
Mr. Jarrod Longcor Chief Operating Officer 1973
Mr. Chad J. Kolean CPA, CPA CFO & Sec. 1964
Mr. Shane Lea Chief Commercial Officer NA
Mr. James V. Caruso President, CEO & Director 1959
Mr. Chad J. Kolean CPA VP, CFO & Secretary 1964
Mr. Darrell Shane Lea Chief Commercial Officer 1973
Dr. Andrei Shustov M.D. Senior Vice President of Medical 1971
Mr. Darrell Shane Lea Chief Commercial Officer 1974
Dr. Andrei Shustov M.D. Senior Vice President of Medical 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…